REVEAL: Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification
Status:
Active, not recruiting
Trial end date:
2037-01-31
Target enrollment:
Participant gender:
Summary
The Randomized EValuation of the Effects of Anacetrapib Through Lipid-modification (REVEAL)
trial aims to determine whether lipid modification with anacetrapib 100mg daily reduces the
risk of coronary death, myocardial infarction (MI) or coronary revascularization
(collectively known as major coronary events) in patients with circulatory problems who have
their Low-density Lipoprotein (LDL) cholesterol level treated with a statin.